June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Gene Therapy of Mucopolysaccharidosis Type VII (MPS VII) with CRISPR/Cas9 Genome Editing
Author Affiliations & Notes
  • Winston W Y Kao
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
  • Tarsis Ferreira
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
  • Yong Yuan
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
  • Fei Dong
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
  • Yueh-Chiang Hu
    Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
  • Mindy Call
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
  • Vivien Jane Coulson-Thomas
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
    Optometry School, Univeristy of Houston, Houston, Texas, United States
  • Jianhua Zhang
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
  • Taylor Rice
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio, United States
  • Footnotes
    Commercial Relationships   Winston Kao, None; Tarsis Ferreira, None; Yong Yuan, None; Fei Dong, None; Yueh-Chiang Hu, None; Mindy Call, None; Vivien Coulson-Thomas, None; Jianhua Zhang, None; Taylor Rice, None
  • Footnotes
    Support  NIH/NEI grants RO1 EY011845, unrestricted Departmental grant of Research to Prevent Blindness and Ohio Eye Research Foundation
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3374. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Winston W Y Kao, Tarsis Ferreira, Yong Yuan, Fei Dong, Yueh-Chiang Hu, Mindy Call, Vivien Jane Coulson-Thomas, Jianhua Zhang, Taylor Rice; Gene Therapy of Mucopolysaccharidosis Type VII (MPS VII) with CRISPR/Cas9 Genome Editing. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3374.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Currently, there is no effective gene therapy treatment for lysosomal storage diseases. Lysosomal enzymes and transporting proteins are secreted via extracellular vesicles (EV). We thus hypothesize that CRISPR genome editing will correct a genetic defect in a fraction of somatic cells ameliorating the pathology via the secretion of EV containing functional enzyme/protein. Gusb mice caused by a single base nonsense deletion mutation in β-glucuronidase (β-Glu/Gusb) manifest a MPS phenotype similar to the human MPS VII (Sly syndrome). We aim to develop a strategy to treat congenital cornea disease using CRISPR genome editing.

Methods : Conventional techniques are used to prepare AAV2-DJ vectors for a binary AAV2-DJ-SpCas9 and AAV2-DJ-sgRNA/DNA-donor and a mono AAV2-DJ-SaCas9/sgRNA/DNA-donor. AAV2-DJ vectors at 1011 viral particles/ml are administered to the experimental mice via tail vein or retro orbital intravenous infusion (ROIV). The experimental mice are subjected to HRTII in vivo confocal microscopy, survival rate and β-Glu histochemistry.

Results : Gusb mice have an age-related increase of corneal haze and an average life span of about 4 months. The onset of death commences around 8 weeks of age. Treatment with binary AAV2-DJ vectors via tail vein infusion produced limited improvements in the reduction of corneal haze and a delayed onset of death by 10 weeks. To improve the treatment efficacy, a mono AAV2-DJ was generated taking the advantage that SaCas9 plasmid DNA is about 500 bp smaller than that of SpCas9 allowing for the insertion of a U6-sgRNA plasmid and a 300 bp DNA donor for repairing the Gusb allele by homology directed repair. The administration of the single AAV2-DJ-SaCas9/sgRNA/DNA-donor via ROIV greatly improved corneal transparency and survival (treated mice are still alive at 28 weeks). Small amounts of β-glu is detected in the liver of treated Gusb mice.

Conclusions : These results suggest that the CRISPR/Cas9 system is an effective treatment for mouse corneal dystrophy e.g., MPS VII. The mono AAV2-DJ-SACas9/sgRNA/DNA-donor vector yielded a better therapeutic efficacy in terms of survival rate and reduction of corneal haze.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×